GPC3 inhibitor (Ablaze/RayzeBio)

N/A

Report date: 2025/03/20 15:16:57

Base Information

Drug NameGPC3 inhibitor (Ablaze/RayzeBio)
Drug Alias NameGlypican-3 (Ablaze RayzeBio)Glypican-3
ClassificationBiologics > Protein drugs > Recombinant polypeptideRadiation-emitting products > Radioactive therapeutic agent
Mechanisms of ActionGlypican-3 inhibitors
TargetsGlypican-3
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesRayzeBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesRayzeBio IncAibozi Pharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A